Terminal complement inhibition and control of hemolysis in patients with paroxysmal nocturnal hemoglobinuria who switched from high-dose eculizumab to ravulizumab: a phase IV, single-arm clinical trial

Lignende værker

• Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization
  af: Anita Hill, et al.
  Udgivet: (2010-04-01)
• Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience
  af: Morag Griffin, et al.
  Udgivet: (2018-08-01)
• Paroxysmal nocturnal hemoglobinuria and thrombosis
  af: A. R. Khisamieva, et al.
  Udgivet: (2026-03-01)
• Severe Hemolysis in a COVID-19 Patient with Paroxysmal Nocturnal Hemoglobinuria
  af: Steve Biko Otieno, et al.
  Udgivet: (2021-01-01)
• Erythropoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria
  af: A. Hill, et al.
  Udgivet: (2007-03-01)